Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-04 04:14 | 2025-10-31 | IONS | IONIS PHARMACEUTICALS INC | LOSCALZO JOSEPH | Director | OPT+S | $75.10 | 16,000 | $1,201,669 | 36,330 |
| 2025-11-04 01:25 | 2025-06-09 | ORGO | Organogenesis Holdings Inc. | NUSSDORF GLENN H | Director, 10% owner | SELL | $3.55 | 22,776 | $80,802 | 335,719 |
| 2025-11-04 01:25 | 2025-05-14 | ORGO | Organogenesis Holdings Inc. | NUSSDORF GLENN H | Director, 10% owner | BUY | $3.06 | 358,495 | $1,096,027 | 358,495 |
| 2025-11-04 03:11 | 2025-10-30 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $1.33 | 189,356 | $251,351 | 3,943,359 |
| 2025-11-04 03:07 | 2025-10-30 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $1.33 | 295,043 | $391,640 | 6,147,610 |
| 2025-11-04 02:00 | 2025-10-30 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% owner | SELL | $1.81 | 112,260 | $202,854 | 28,500 |
| 2025-11-04 02:00 | 2025-10-30 | BGMS | Bio Green Med Solution, Inc. | Kua Khai Loon | 10% owner | SELL | $1.80 | 242,477 | $436,459 | 0 |
| 2025-11-04 02:00 | 2025-10-30 | BGMS | Bio Green Med Solution, Inc. | Ong Yee Lung | 10% owner | SELL | $1.80 | 248,814 | $447,865 | 0 |
| 2025-11-04 04:14 | 2025-10-30 | IONS | IONIS PHARMACEUTICALS INC | WENDER JOSEPH H | Director | SELL | $74.02 | 28,000 | $2,072,577 | 64,035 |
| 2025-10-31 23:31 | 2025-10-30 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $102.92 | 4,000 | $411,661 | 48,034 |
| 2025-10-31 23:30 | 2025-10-30 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $103.16 | 21,800 | $2,248,943 | 49,086 |
| 2025-10-31 23:15 | 2025-10-30 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $3.17 | 4,115 | $13,045 | 46,175 |
| 2025-10-31 22:30 | 2025-10-29 | SYBX | SYNLOGIC, INC. | Dooley Mary Beth | Officer | SELL | $1.81 | 157 | $284 | 12,744 |
| 2025-11-01 00:15 | 2025-10-31 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner | BUY | $1.42 | 150,000 | $213,435 | 214,386,448 |
| 2025-10-31 23:38 | 2025-10-29 | BBIO | BridgeBio Pharma, Inc. | MCCORMICK FRANK | Director | SELL | $66.58 | 198,359 | $13,206,524 | 679,979 |
| 2025-10-31 23:09 | 2025-10-29 | REGN | REGENERON PHARMACEUTICALS, INC. | POON CHRISTINE A | Director | OPT+S | $654.27 | 6,500 | $4,252,745 | 2,352 |
| 2025-11-01 01:00 | 2025-10-29 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% owner | SELL | $1.83 | 110,749 | $203,114 | 140,760 |
| 2025-11-01 00:12 | 2025-10-29 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $442.37 | 8,000 | $3,538,949 | 130 |
| 2025-11-01 00:20 | 2025-10-30 | PTCT | PTC THERAPEUTICS, INC. | Reeve Emma | Director | OPT+S | $69.50 | 15,666 | $1,088,787 | 6,666 |
| 2025-10-31 03:00 | 2025-10-28 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Officer | OPT+S | $30.06 | 16,665 | $500,987 | 82,139 |
| 2025-10-31 02:02 | 2025-10-28 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd | Director, Officer | SELL | $25.03 | 40,000 | $1,001,032 | 806,440 |
| 2025-10-30 23:47 | 2025-10-28 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $41.00 | 100 | $4,100 | 31,086 |
| 2025-10-30 23:44 | 2025-10-28 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Shulman Joseph | Officer | OPT+S | $115.01 | 2,815 | $323,750 | 8,509 |
| 2025-10-31 01:06 | 2025-10-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | Officer | OPT+S | $12.80 | 3,130 | $40,054 | 43,876 |
| 2025-10-31 01:02 | 2025-10-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $12.80 | 3,644 | $46,631 | 50,897 |
| 2025-10-31 01:01 | 2025-10-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Officer | OPT+S | $12.80 | 4,087 | $52,300 | 76,751 |
| 2025-10-30 23:45 | 2025-10-28 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Officer | SELL | $30.00 | 2,662 | $79,860 | 124,662 |
| 2025-10-30 23:45 | 2025-10-28 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer | OPT+S | $30.32 | 120,000 | $3,638,436 | 419,173 |
| 2025-10-30 15:49 | 2025-10-28 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Officer | SELL | $20.76 | 96,859 | $2,010,580 | 1,091,374 |
| 2025-10-30 23:31 | 2025-10-28 | MPLT | MapLight Therapeutics, Inc. | Novo Holdings A/S | 10% owner | BUY | $17.00 | 952,941 | $16,199,997 | 3,686,622 |
| 2025-10-31 01:00 | 2025-10-28 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% owner | SELL | $1.83 | 13,111 | $23,967 | 251,509 |
| 2025-10-30 23:37 | 2025-10-30 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $450.34 | 11,000 | $4,953,761 | 36,781 |
| 2025-10-30 23:30 | 2025-10-27 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $415.47 | 8,000 | $3,323,728 | 130 |
| 2025-10-31 01:09 | 2025-10-28 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $41.43 | 10,560 | $437,487 | 44,440 |
| 2025-10-30 23:25 | 2025-10-30 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $62.86 | 5,000 | $314,300 | 358,108 |
| 2025-10-30 03:43 | 2025-10-23 | TTRX | Turn Therapeutics Inc. | Chesed Abraham | BUY | $4.60 | 14,286 | $65,716 | 1,447,268 | |
| 2025-10-29 23:31 | 2025-10-27 | NUVL | Nuvalent, Inc. | Shair Matthew | Director | SELL | $100.26 | 60,000 | $6,015,462 | 203,322 |
| 2025-10-29 23:30 | 2025-10-27 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $22.93 | 1,073 | $24,604 | 184,338 |
| 2025-10-29 15:00 | 2025-10-23 | NVCT | Nuvectis Pharma, Inc. | Mosseri Marlio Charles | 10% owner | BUY | $6.18 | 154,770 | $957,082 | 3,136,576 |
| 2025-10-29 23:16 | 2025-10-28 | MLPT | MapLight Therapeutics, Inc. | Catalyst4, Inc. | 10% owner | BUY | $17.00 | 5,441,176 | $92,499,992 | 19,697,464 |
| 2025-10-29 23:30 | 2025-10-27 | LQDA | Liquidia Corp | Adair Jason | Officer | SELL | $22.93 | 692 | $15,868 | 174,998 |
| 2025-10-29 15:54 | 2025-10-28 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | Officer | SELL | $20.00 | 5,000 | $100,000 | 92,138 |
| 2025-10-30 02:21 | 2025-10-27 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $1.62 | 276,017 | $446,402 | 6,442,653 |
| 2025-10-29 23:24 | 2025-10-27 | NUVB | Nuvation Bio Inc. | Hattersley Gary | Officer | OPT+S | $5.02 | 100,000 | $502,460 | 0 |
| 2025-10-29 23:02 | 2025-10-27 | AGIO | Agios Pharmaceuticals Inc. | Gheuens Sarah | Officer | OPT+S | $43.92 | 3,302 | $145,024 | 61,727 |
| 2025-10-30 00:04 | 2025-10-28 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $4.96 | 5,551 | $27,541 | 0 |
| 2025-10-30 00:10 | 2025-10-27 | BBIO | BridgeBio Pharma, Inc. | MCCORMICK FRANK | Director | SELL | $65.00 | 1,641 | $106,665 | 878,338 |
| 2025-10-30 02:22 | 2025-10-27 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $1.62 | 177,145 | $286,497 | 4,132,715 |
| 2025-10-30 02:21 | 2025-10-27 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $1.62 | 276,017 | $446,402 | 6,442,653 |
| 2025-10-30 01:00 | 2025-10-27 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% owner | SELL | $2.12 | 120,250 | $254,690 | 264,620 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.